---
document_datetime: 2024-10-11 14:55:01
document_pages: 20
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/gardasil-9-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: gardasil-9-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 12.1736957
conversion_datetime: 2025-12-23 03:30:07.538231
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Gardasil 9

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                 | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| IAIN/0076            | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                        | 09/10/2024                          |                                             | SmPC and PL                      |           |
| II/0074              | B.II.b.5.e - Change to in-process tests or limits applied during the manufacture of the finished product - Widening of the approved IPC limits, which | 19/09/2024                          | n/a                                         |                                  |           |

1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|           | have a significant effect on overall quality of the product                                                                                                                                                                                                                                                                                                                                                |            |     |          | may finished   |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|----------|----------------|
| IB/0075/G | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other | 09/07/2024 | n/a |          | variation      |
| IA/0073   | B.I.b.2.b - Change in test procedure for AS or starting material/reagent/intermediate - Deletion of a test procedure for the AS or a starting material/reagent/intermediate, if an alternative test procedure is already authorised                                                                                                                                                                        | 09/05/2024 | n/a |          |                |
| IB/0072   | B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS                                                                                                                                                                                                                                                                                           | 26/03/2024 | n/a |          |                |
| IB/0071/G | This was an application for a group of variations. B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place Implementation of changes foreseen in an                                                                     | 26/03/2024 |     | Annex II | B.I.e.5.c -    |

<div style=\"page-break-after: always\"></div>

|         | approved change management protocol - For a biological/immunological medicinal product                                                                                                                                                                                                                                                                         |            |     |             |                                                                                                                                                                                                                                                                                                                                                                                                            |
|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0069 | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                              | 21/03/2024 |     | SmPC and PL | Gardasil SmPC section 5.1 has been modified to include updated information on long term-effectiveness. The numbers on years pot-dose, median follow-up years and number of people followed have been updated.                                                                                                                                                                                              |
| IB/0070 | B.II.b.1.z - Replacement or addition of a manufacturing site for the FP - Other variation                                                                                                                                                                                                                                                                      | 05/01/2024 | n/a |             |                                                                                                                                                                                                                                                                                                                                                                                                            |
| IB/0068 | B.II.b.1.z - Replacement or addition of a manufacturing site for the FP - Other variation                                                                                                                                                                                                                                                                      | 22/08/2023 | n/a |             |                                                                                                                                                                                                                                                                                                                                                                                                            |
| IB/0067 | B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)                                                                                                                                                                                                                         | 20/06/2023 | n/a |             |                                                                                                                                                                                                                                                                                                                                                                                                            |
| IB/0066 | B.II.g.5.c - Implementation of changes foreseen in an approved change management protocol - For a biological/immunological medicinal product                                                                                                                                                                                                                   | 19/06/2023 | n/a |             |                                                                                                                                                                                                                                                                                                                                                                                                            |
| II/0063 | Update of section 4.6 of the SmPC in order to include additional information on exposure during pregnancy based on the final report of the US Pregnancy Registry, listed as a category 3 study in the RMP (MEA 003.1 is fulfilled with this procedure). The Package Leaflet is updated accordingly. The RMP version 5.1 has been approved with this procedure. | 12/05/2023 |     | SmPC and PL | The SmPC text Section 4.6 has been updated to include the results of the pregnancy registry. The recommendation to avoid Gardasil 9 in case of pregnancy is maintained. The Package leaflet was updated accordingly to specify that if a woman is pregnant or becomes pregnant during the course of vaccination, it is recommended to postpone or interrupt vaccination until they are no longer pregnant. |

<div style=\"page-break-after: always\"></div>

|                     | data                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |            |            |      |                                                                                                                                            |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|--------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10389 /202206 | Periodic Safety Update EU Single assessment - human papillomavirus 9-valent vaccine (recombinant, adsorbed)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 26/01/2023 | 31/03/2023 | SmPC | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10389/202206. |
| IB/0064             | B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 23/01/2023 | n/a        |      |                                                                                                                                            |
| II/0061             | B.II.g.2 - Introduction of a post approval change management protocol related to the finished product                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 15/12/2022 | n/a        |      |                                                                                                                                            |
| II/0060/G           | This was an application for a group of variations. B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch release/control, and secondary packaging, for biol/immunol medicinal products or pharmaceutical forms manufactured by complex manufacturing processes B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.e.4.c - Change in shape or dimensions of the container or closure (immediate packaging) - Sterile medicinal products | 01/12/2022 | n/a        |      |                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

| IB/0062   | B.II.g.5.c - Implementation of changes foreseen in an approved change management protocol - For a biological/immunological medicinal product                                                                                                                                                                                                                                                                                                                                                                                                                                     | 18/11/2022   | n/a        |          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| WS/2336   | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Update of section 5.1 of the SmPC to add the effect of vaccination campaigns on the reduction in the incidence of Juvenile-onset Recurrent Respiratory Papillomatosis (JoRRP) based upon published observational studies. In addition, the MAH took the opportunity to introduce minor editorial changes to the SmPC. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance | 13/10/2022   | 31/03/2023 | SmPC     | The following wording about the effect of vaccination campaigns on the reduction in the incidence of Juvenile- onset Recurrent Respiratory Papillomatosis (JoRRP) based upon published observational studies was agreed for addition to SmPC section 5.1: 'JoRRP is caused by upper airway infection primarily with HPV types 6 and 11, acquired vertically (mother-to-child) during childbirth. Observational studies in the US and Australia have shown that the introduction of Gardasil since 2006 has led to declines in the incidence of JoRRP at population level.' |
| IG/1529/G | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release)                                                                                 | 06/07/2022   | 31/03/2023 | Annex II |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

|         | and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |            |            |                        |                                                                                                                                            |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|--------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0055 | B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 10/06/2022 | n/a        |                        |                                                                                                                                            |
| IB/0056 | B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 09/06/2022 | n/a        |                        |                                                                                                                                            |
| T/0054  | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 14/03/2022 | 29/04/2022 | SmPC, Labelling and PL |                                                                                                                                            |
| II/0053 | Update of section 5.1 of the SmPC in order to update long-term effectiveness and immunogenicity data following the final results of the Gardasil 9 long-term follow-up (LTFU) paediatric study V503-002-20, listed as a category 3 study in the RMP. V503-002-20 is a LTFU extension of Study V503-002 (base study: a 3-year immunogenicity study of the 9vHPV vaccine in girls and boys 9 to 15 years of age, which assessed the immunogenicity and effectiveness of the 9vHPV vaccine through 10 years post dose 3. In addition, the MAH took the opportunity to make some minor editorial changes (spacings) and included the updated long term follow-up data already approved for the qHPV vaccine following V501-167 extension study. The details of local | 24/03/2022 | 31/03/2023 | SmPC and PL            | Please refer to Scientific Discussion EMEA/H/C/003852/II/0053 For more information, please refer to the Summary of Product Characteristics |

<div style=\"page-break-after: always\"></div>

|                     | representatives for the MAH in the Package Leaflet is also updated. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                               |            |            |             |                                   |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-----------------------------------|
| PSUSA/10389 /202106 | Periodic Safety Update EU Single assessment - human papillomavirus 9-valent vaccine (recombinant, adsorbed)                                                                                                                                                         | 13/01/2022 | n/a        |             | PRAC Recommendation - maintenance |
| IB/0052             | B.II.f.1.d - Stability of FP - Change in storage conditions of the finished product or the diluted/reconstituted product                                                                                                                                            | 10/11/2021 | 28/04/2022 | SmPC and PL |                                   |
| IB/0048/G           | This was an application for a group of variations. B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure | 15/10/2021 | n/a        |             |                                   |
| IB/0051             | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                       | 13/10/2021 | n/a        |             |                                   |
| IB/0047             | B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS                                                                                                                                                    | 05/10/2021 | n/a        |             |                                   |

<div style=\"page-break-after: always\"></div>

| II/0046             | B.II.g.2 - Introduction of a post approval change management protocol related to the finished product                                                                                                                                                                  | 16/09/2021   | n/a        |             |                                   |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-------------|-----------------------------------|
| IA/0049             | B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the dossier) - Replacement or addition of a supplier                                                                                                                             | 10/08/2021   | n/a        |             |                                   |
| WS/2037             | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.e.2 - Introduction of a post approval change management protocol related to the AS                                   | 24/06/2021   | n/a        |             |                                   |
| II/0044             | B.II.b.2.b - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place for a biol/immunol product and any of the test methods at the site is a biol/immunol method | 28/01/2021   | n/a        |             |                                   |
| PSUSA/10389 /202006 | Periodic Safety Update EU Single assessment - human papillomavirus 9-valent vaccine (recombinant, adsorbed)                                                                                                                                                            | 14/01/2021   | n/a        |             | PRAC Recommendation - maintenance |
| II/0040             | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                      | 14/01/2021   | 28/04/2022 | SmPC and PL |                                   |
| II/0043/G           | This was an application for a group of variations. B.I.a.2.c - Changes in the manufacturing process of                                                                                                                                                                 | 29/10/2020   | n/a        |             |                                   |

<div style=\"page-break-after: always\"></div>

|           | the AS - The change refers to a [-] substance in the manufacture of a biological/immunological substance which may have a significant impact on the medicinal product and is not related to a protocol B.I.a.4.b - Change to in-process tests or limits applied during the manufacture of the AS - Addition of a new in-process test and limits                                                                                                                                         |            |     |             |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-------------|
| IB/0041/G | This was an application for a group of variations. B.II.b.1.z - Replacement or addition of a manufacturing site for the FP - Other variation B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished Other variation                                                                                                | 30/07/2020 | n/a | product -   |
| II/0038/G | This was an application for a group of variations. B.I.b.1.a - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits for medicinal products subject to OCABR B.I.b.1.a - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits for medicinal products subject to OCABR Change in the specification parameters | 23/07/2020 | n/a | B.I.b.1.f - |

<div style=\"page-break-after: always\"></div>

|                     | and/or limits of an AS, starting material/intermediate/reagent - Change outside the approved specifications limits range for the AS                                                                                                                                                                                                                                                                 |            |            |                                  |                                   |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|-----------------------------------|
| IA/0039             | A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release)                                                                                                                                                                                                    | 29/06/2020 | n/a        |                                  |                                   |
| II/0037/G           | This was an application for a group of variations. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance | 17/04/2020 | 24/11/2020 | SmPC, Annex II, Labelling and PL |                                   |
| PSUSA/10389 /201906 | Periodic Safety Update EU Single assessment - human papillomavirus 9-valent vaccine (recombinant, adsorbed)                                                                                                                                                                                                                                                                                         | 16/01/2020 | n/a        |                                  | PRAC Recommendation - maintenance |
| R/0035              | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                             | 14/11/2019 | 16/01/2020 | SmPC, Labelling and PL           |                                   |
| II/0033             | Update of sections 4.2, 4.6, 4.8 and 5.1 of the SmPC in order to update the safety and immunogenicity information based on final results from study V503-                                                                                                                                                                                                                                           | 28/11/2019 | 24/11/2020 | SmPC and PL                      |                                   |

<div style=\"page-break-after: always\"></div>

|                     | P004 listed as a category 3 study in the RMP (MEA007); this is an open-label phase III clinical trial to study the immunogenicity and tolerability of Gardasil 9 in adult women (27 to 45 year-olds) compared to young adult women (16 to 26 year- olds); the Package Leaflet is updated accordingly. The RMP version 4.1 has also been submitted. In addition, the Marketing authorisation holder (MAH) took the opportunity to update Section 4.4 of the SmPC according to the Guideline on quality aspects included in the product information for vaccines for human use (EMA/CHMP/BWP/133540/2017), and to include editorial changes in Section 5.1 of the SmPC The requested variation proposed amendments to the Summary of Product Characteristics and Package Leaflet and to the Risk Management Plan (RMP). C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance   |            |            |                     |                                   |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|---------------------|-----------------------------------|
| IAIN/0034           | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 14/08/2019 | n/a        |                     |                                   |
| PSUSA/10389 /201812 | Periodic Safety Update EU Single assessment - human papillomavirus 9-valent vaccine (recombinant, adsorbed)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 11/07/2019 | n/a        |                     | PRAC Recommendation - maintenance |
| IAIN/0032           | B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 29/04/2019 | 25/07/2019 | SmPC, Labelling and |                                   |

<div style=\"page-break-after: always\"></div>

|           | tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes                                                                                                                                                                                                                                                                                                                                                                                                  |            |            | PL          |                       |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-----------------------|
| IB/0031/G | This was an application for a group of variations. B.II.d.1.b - Change in the specification parameters and/or limits of the finished product - Tightening of specification limits for medicinal products subject to OCABR B.II.d.1.d - Change in the specification parameters and/or limits of the finished product - Deletion of a non-significant specification parameter B.II.d.2.b - Change in test procedure for the finished product - Deletion of a test procedure if an already authorised | 15/04/2019 | n/a        |             | alternative method is |
| II/0029   | C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required                                                                                                                                                                                                     | 14/02/2019 | n/a        |             |                       |
| II/0028   | Update of section 5.1 of the SmPC in order to consolidate the existing information following a request of the CHMP (EMEA/H/C/003852/II/0024/G). In addition, the Marketing authorisation holder (MAH) took the opportunity to update the list of local representatives in the Package Leaflet. C.I.z - Changes (Safety/Efficacy) of Human and Medicinal Products - Other variation                                                                                                                 | 17/01/2019 | 25/07/2019 | SmPC and PL | Veterinary            |

<div style=\"page-break-after: always\"></div>

| PSUSA/10389 /201806   | Periodic Safety Update EU Single assessment - human papillomavirus 9-valent vaccine (recombinant, adsorbed)                                                                                                                                                                                                                                                                                                                                                                                                                            | 17/01/2019   | n/a        |      | PRAC Recommendation - maintenance   |
|-----------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------|-------------------------------------|
| II/0025               | Changes in the manufacturing process of the active substance (Human Papillomavirus 9-valent Vaccine (Recombinant, adsorbed), specifically the HPV 16 L1 protein) to increase the lifetime of filters membranes and chromatography resins. The requested variation proposed no amendments to the Product Information. B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological substance which may have a significant impact on the medicinal | 26/07/2018   | n/a        |      |                                     |
| II/0024/G             | This was an application for a group of variations. Update of section 5.1 of the SmPC with information on results from long-term follow-up (LTFU) studies. Specifically: - addition of a long-term effectiveness sub- section, based on the first interim reports from the 9vHPV studies V503-021-01 and V503-002-20 (two category 3 studies included in the pharmacovigilance plan of the 9vHPV vaccine - MEA-004 and MEA 005, respectively), - update of the immunogenicity sub-section                                               | 26/07/2018   | 25/07/2019 | SmPC |                                     |

<div style=\"page-break-after: always\"></div>

|                     | above as well as final results from studies V503-001- 04 and V503-010-01, - update of the qHPV clinical data based on the efficacy/effectiveness results and/or immunogenicity results of the qHPV studies V501-015-21 (4th interim report), V501-019-21 (final study report), V501-020- 21 (final study report) and the extension of study V501-167. The MAH also took the opportunity to introduce minor amendments throughout the product information. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance   |            |     |                                   |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------|
| IB/0026             | B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 24/07/2018 | n/a |                                   |
| PSUSA/10389 /201712 | Periodic Safety Update EU Single assessment - human papillomavirus 9-valent vaccine (recombinant, adsorbed)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 12/07/2018 | n/a | PRAC Recommendation - maintenance |
| PSUSA/10389 /201706 | Periodic Safety Update EU Single assessment - human papillomavirus 9-valent vaccine                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 11/01/2018 | n/a | PRAC Recommendation - maintenance |

<div style=\"page-break-after: always\"></div>

|           | (recombinant, adsorbed)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |            |            |                  |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------|
| IB/0022   | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 05/01/2018 | n/a        |                  |
| N/0021    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 27/11/2017 | 19/02/2018 | Labelling and PL |
| II/0019/G | This was an application for a group of variations. B.II.b.1.c: To add MSD International GmbH T/A MSD Ireland (Carlow), Dublin Road, Carlow, Co. Carlow, Ireland as an alternative site responsible for final formulated bulk pooling and primary packaging of Gardasil 9 suspension for injection in pre-filled syringes. B.II.b.2.a: To add MSD International GmbH T/A MSD Ireland (Carlow), Dublin Road, Carlow, Co. Carlow, Ireland as an alternative site responsible for batch/control testing for bacterial endotoxin and sterility tests for Gardasil 9 suspension for injection in pre-filled syringes. B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch release/control, and secondary packaging, for biol/immunol medicinal products or pharmaceutical forms manufactured by complex manufacturing processes | 13/07/2017 | n/a        |                  |

<div style=\"page-break-after: always\"></div>

|                     | B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place                                                                                 |            |            |                        |                                   |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-----------------------------------|
| PSUSA/10389 /201612 | Periodic Safety Update EU Single assessment - human papillomavirus 9-valent vaccine (recombinant, adsorbed)                                                                                                                                                | 06/07/2017 | n/a        |                        | PRAC Recommendation - maintenance |
| N/0018              | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                           | 24/03/2017 | 19/02/2018 | PL                     |                                   |
| IG/0777             | A.1 - Administrative change - Change in the name and/or address of the MAH                                                                                                                                                                                 | 23/02/2017 | 19/02/2018 | SmPC, Labelling and PL |                                   |
| II/0013             | B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological substance which may have a significant impact on the medicinal product and is not related to a protocol | 19/01/2017 | n/a        |                        |                                   |
| PSUSA/10389 /201606 | Periodic Safety Update EU Single assessment - human papillomavirus 9-valent vaccine (recombinant, adsorbed)                                                                                                                                                | 12/01/2017 | n/a        |                        | PRAC Recommendation - maintenance |
| IG/0758             | A.1 - Administrative change - Change in the name and/or address of the MAH                                                                                                                                                                                 | 11/01/2017 | 03/03/2017 | SmPC, Labelling and PL |                                   |
| N/0014              | Update of the package leaflet with revised contact details of the local representatives.                                                                                                                                                                   | 21/12/2016 | 03/03/2017 | PL                     |                                   |

<div style=\"page-break-after: always\"></div>

|                     | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                            |            |            |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10389 /201512 | Periodic Safety Update EU Single assessment - human papillomavirus 9-valent vaccine (recombinant, adsorbed)                                                                                                                                                                                                                                                                                                 | 07/07/2016 | n/a        |                                  | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| II/0010             | Update of section 5.1 of the SmPC in order to include clinical data based on the final clinical study report for the paediatric study V503-020 (GDS07C), provided as per the requirements of article 46 of the paediatric regulation. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                     | 12/05/2016 | 03/03/2017 | SmPC                             | Study GDS07C compared immune responses to 9vHPV vaccine with immune responses to 4vHPV vaccine in 16-26 years old boys and men. The responses to the 4 common HPV types (6, 11, 16 and 18) were shown to be non- inferior in the 9vHPV group compared to the 4vHPV group. The responses to the 5 new HPV types were greater in the 9vHPV group compared to the 4 vHPV group. The results were overall in agreement with the results previously shown in women 16-26 years of age. The safety results confirm the safety profile of the 9vHPV vaccine, and non new safety signal was detected. |
| IB/0011             | B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS                                                                                                                                                                                                                                                                                            | 26/04/2016 | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| II/0004             | Update of sections 4.2 and 5.1 of the SmPC in order to add an alternative 2-dose vaccination schedule for children from 9 to 14 years of age based on study results of Protocol V503-010 and section 4.8 of the SmPC in order to add bronchospasm and urticaria. The Package Leaflet is updated accordingly. For clarity, minor amendments have been included in Sections 4.4, and 4.6 and 5.1 of the SmPC. | 25/02/2016 | 04/04/2016 | SmPC, Annex II, Labelling and PL | The MAH provided the results of a study V503-010 to investigate an alternative 2-dose vaccination schedule for children from 9 to 14 years of age. Results showed comparable immune responses in 2-dose recipients compared to the 3-dose recipients and support the proposed addition of a 2-dose schedule. For completeness and to align with the SmPC of Gardasil section 4.8 of the SmPC was updated to add bronchospasm and urticaria.                                                                                                                                                   |

<div style=\"page-break-after: always\"></div>

|          | (MAH) took the opportunity to update the list of local representatives in the Package Leaflet, to bring the PI in line with the latest QRD template version 10 and to combine the SmPCs of the suspension for injection and the suspension for injection in a pre filled syringe. Furthermore, the MAH implemented minor linguistic revisions in the Portuguese, Czeck and Slovak texts. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data   |            |            |      |                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0007  | Update of section 5.1 of SmPC with the results of 4 long term follow-up studies (final study P018-11 and interim reports for Studies P015-21, P019-21 and P020-21). C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                        | 01/04/2016 | 03/03/2017 | SmPC | Section 5.1 of SmPC was updated with the results of 4 long term follow-up studies in adolescents (final study P018-11 and interim reports for long term follow-up studies in young/mid-adult women and young men (Studies P015-21, P019-21 and P020-21). In the long-term extension registry study for 16-23 year old women vaccinated with qHPV vaccine, a durable protection was statistically demonstrated to approximately 8 years. |
| IB/0008  | B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate                                                                                                                                                                                                                                                                                                 | 26/01/2016 | n/a        |      |                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| A20/0001 | Pursuant to Article 20 of Regulation (EC) No 726/2004, the European Commission requested on 09 July 2015 the opinion of the European Medicines Agency on whether there is evidence of a causal                                                                                                                                                                                                                                                                                                               | 19/11/2015 | 12/01/2016 |      | Please refer to the assessment report: Cervarix: EMEA/H/A20/1421/C/0721/0071 Gardasil: EMEA/H/A20/1421/C/0703/0060 Gardasil 9: EMEA/H/A20/1421/C/3852/0001                                                                                                                                                                                                                                                                              |

<div style=\"page-break-after: always\"></div>

|         | association between HPV vaccination and CRPS and/or POTS, and if available information may require updates to the advice to healthcare professionals and patients, including changes to product information or other regulatory measures on the marketing authorisations concerned. As the request results from the evaluation of data resulting from pharmacovigilance activities, the CHMP opinion should be adopted on the basis of a recommendation of the Pharmacovigilance Risk Assessment Committee.   |            |            |    | Silgard: EMEA/H/A20/1421/C/0732/0054   |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----|----------------------------------------|
| N/0006  | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                              | 21/12/2015 | 04/04/2016 | PL |                                        |
| IG/0625 | C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the PSMF location                                                                                                                                                                                                                                                                                                                                               | 16/11/2015 | n/a        |    |                                        |
| II/0003 | B.I.a.1.e - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The change relates to a biological AS or a starting material [-] used in the manufacture of a biological/immunological product                                                                                                                                                                                                                                                                           | 15/10/2015 | n/a        |    |                                        |
| II/0002 | B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological substance which may have a significant impact on the medicinal                                                                                                                                                                                                                                                                                             | 17/09/2015 | n/a        |    |                                        |

<div style=\"page-break-after: always\"></div>

| product and is not related to a protocol   |
|--------------------------------------------|